FL-WAX
22.11.2021 14:51:07 CET | Business Wire | Press release
Metasaurs , one of the fastest-growing NFT communities in the world, and WAX ($3.5B market cap), the most utilized blockchain in the world for games, processing three-quarters of all game-related transactions daily, announced a ground-breaking partnership to bring new world-class P2E (play-to-earn) games to the WAX ecosystem.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211122006228/en/
The creators of Metasaurs and founders of WAX will be co-founding a new NFT gaming studio, MetaGames to develop new game projects including the official Metasaurs Game and the launch of the RAWR token to be released in Q1 2022.
Since its inception in 2017, WAX has been coined “The King of NFTs,” but it’s so much more. WAX’s vIRL® technology is leading the future of digital commerce and it is the #1 blockchain by transaction volume in the world. It currently has more than 8M monthly users and is growing 400k+ users per month.
The WAX gaming-optimized blockchain processes 15 million transactions per day and is the #2 layer-1 blockchain behind only Ethereum in daily and 30 day NFT sales volume. Alien Worlds, one of the most popular games in the world, is built on the WAX blockchain, and independently boasts a $2.3B market cap for its own in-game economy.
"The foundation of WAX was built on gaming,” said William E. Quigley, co-founder of WAX, “and the official Metasaurs Game is the perfect use case for a play-to-earn gaming franchise created on WAX, taking advantage of our high volume transaction capacity, unique fee structure of no minting and gifting transaction fees, and energy efficient and low carbon footprint.”
Metasaurs are Dinosaur-Bored Ape hybrids of the popular Bored Ape Yacht Club NFT. The extended storyline, based on Dr. DMT, creating the Metasaurs, unlocks endless creative potential with regard to future games, avatars, and other multi-media on the WAX platform and across the emerging metaverse.
"It is our mission to create fun games which will share their economies with the lifeblood of the community—the players—rather than siphoning all value only to the publishers,” said Merlin Kauffman, creator of Metasaurs. ”Blockchain technology is best suited for this use-case, and we are excited to partner with WAX to create differentiated gaming experiences for the mass market."
“Merlin is a grassroots thought-leader in the NFT space,” said Quigley. “His track record building one of the most passionate fastest-growing NFT communities combined with our deep knowledge of NFT gaming economies put us in a privileged position to co-create the official Metasaurs Game. Our gaming studio, MetaGames, has all the right ingredients to create a series of successful play-to-earn gaming franchises.”
Quigley continued, “As we spend an increasing amount of time virtually than ever before, NFTs pave a way for users to have a stake in these new applications and digital worlds. WAX is at the forefront of this gaming evolution in the way we live online, building tools in a way that benefits everyone involved.”
About Metasaurs
The genesis Metasaurs collection is 9,999 NFTs created by Dr. DMT in The Lab from 300+ hand-drawn traits, each Metasaur consists of between 4-7 combined traits, of various rarities. Dr. DMT is authentic BAYC Ape #4588, and he is constantly developing new formulas to expand the Metasaurs experiment. The possibilities are endless, like the infinite lifespans of these Metasaurs on the blockchain .
About WAX - The King of NFTs
The Worldwide Asset eXchange ™ (WAX), aka the King of NFTs, is the world’s #1 blockchain, as measured by number of users and transactions, according to Dappradar.com. WAX’s mission is to bring NFTs to the mass market in the safest, most secure, environmentally friendly, and easy-to-use marketplace in the world. WAX is also the leading entertainment NFT network — in 2018, WAX introduced vIRLs® , giving consumer product companies the ability to directly link NFTs to physical consumer products.
About MetaGames Studio
Creators of world-class games, we are building the future of play-to-earn gaming experiences on the WAX blockchain. Co-founded by William Quigley, Merlin Kauffman, and Ben Bindell in 202, with initial studio development of the official Metasaurs Game and RAWR token to be released in Q1 2022. MetaGames ’ mission is to build branded social gaming communities that share their economies with the players, rather than siphoning all of the value only to the game publishers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211122006228/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom